Name
GS2-02 - Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/ HER2- advanced / metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy
Date & Time
Tuesday, December 7, 2021
Speakers
Virtual Session Link